Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2024-03-12 00:00:00 ET · period of report 2024-03-08 · accession 0001628280-24-010751 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-12 | 2024-03-08 | BLFS | Ellingson Rachel | Dir | A - Grant | — | +11.3K | 42.9K | +36% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-08 | A | A | 11,264 | — | 42,949 | D | — | — | (F1) The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date. |